- Conditions
- Surgical Procedure, Unspecified, Pain, Postoperative
- Interventions
- Ropivacaine
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
Clinical trials at Stanford Medicine
Sites in Stanford & Palo Alto, CA
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Live official records
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Conditions
- Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Sotorasib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 828
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 561 more
- Conditions
- Ischemic Stroke
- Interventions
- Endovascular thrombectomy with any FDA-approved category POL or NRY device, Medical Management
- Device · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 34 more
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
- Conditions
- Aortic Stenosis Symptomatic
- Interventions
- Siegel Transcatheter Aortic Valve (TAVR)
- Device
- Lead sponsor
- MiRus
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Palo Alto, California • Naples, Florida + 5 more
- Conditions
- PreDiabetes, Diabetes Mellitus, Type 2, Healthy
- Interventions
- Post prandial testing
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
Gravitas Feeding Tube System Placement Validation in Neonates
- Conditions
- Nasogastric Tube
- Interventions
- Gravitas FT and Gravitas FT Monitor guidance
- Device
- Lead sponsor
- Gravitas Medical, Inc.
- Industry
- Eligibility
- 0 Weeks to 2 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Stanford, California • Savannah, Georgia • Boston, Massachusetts + 2 more
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
- Conditions
- B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
- Interventions
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Questionnaire Administration, NKTR-255
- Biological · Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2035
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Atrial Fibrillation, Arrhythmias, Cardiac
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
COMparison of Physiological Algorithms for Real-time Evaluation of Atrial Fibrillation
- Conditions
- Atrial Fibrillation, Abnormal Heart Rhythms
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Hypertension Association, Inc.
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Sacramento, California • San Francisco, California + 40 more
ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis
- Conditions
- Aortic Valve Stenosis
- Interventions
- TAVR with CENTERA THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
- Conditions
- Arterial Bleeding in Solid Organs and Peripheral Arteries
- Interventions
- Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter
- Device
- Lead sponsor
- Instylla, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Long Beach, California • Stanford, California + 17 more
About this Stanford Medicine institution page
- What this page lists
- ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, trials led by Stanford University at any site, browse by condition, or browse by U.S. city.